Hummingbird Bioscience, an innovative clinical-stage biotechnology company focused on developing precision therapies against difficult-to-treat targets, today announced a Trials in Progress poster presentation highlighting the Phase 1 clinical trial design for HMBD-002. HMBD-002 is a unique antibody against VISTA, developed ...